greenovation Biotech Strengthens Corporate Management
News May 07, 2014
greenovation Biotech GmbH welcomes Andreas Hartmann, Ph.D. as the new Chief Business Officer. Prior to joining greenovation Dr. Hartmann established and managed the German operations for Therabel and Emergent BioSolutions and held local as well as international management, business development and marketing & sales positions at Emergent BioSolutions, Bavarian Nordic, Ares Serono, Sanofi-Winthrop and Janssen-Cilag.
With greenovation having passed the strategic turning point from an expression platform developer and service provider towards developing customized protein biopharmaceuticals, Dr. Hartmann will intensify the company's international efforts in establishing developmental collaborations and out-licensing/partnering of its advanced lead candidates and selected programs.
greenovation's proprietary Physcomitrella-based BryoTechnology™-platform is suitable for expressing complex multi-purpose proteins. In line with streamlining the business focus the BryoTechnology™-platform has now preferentially been dedicated to development and production of demanding proteins for pharmaceutical use.
The company's lead candidates, targeting unmet medical needs in orphan indications, are spearheaded by recombinant moss Alpha-Galactosidase, to be developed as enzyme-replacement Therapy (ERT) for patients with Fabry Disease. The pre-clinical development of moss Alpha-Galactosidase is close to being completed. With GMP-manufacturing and protein analytics having been fully established greenovation is confident to move this first ever moss-expressed biopharmaceutical candidate into clinical development in autumn 2014.
“We are pleased to welcome Dr. Hartmann to join greenovation's management team. His appointment underlines the company's recent clear cut specialization in biopharmaceuticals. Dr. Hartmann's extensive executive and hands-on operational knowledge and experience in international (bio)pharmaceutical industry makes him ideally qualified to help further developing and achieving greenovation's business goals and future progress", said Günter Steffen, Chairman of greenovation's Advisory Board.
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
The Protein and the PauparNews
Non-coding RNAs (ncRNA) exist in a limbo within cells, having been created from genes but never destined to be turned into functional protein. A ncRNA called Paupar has been shown to regulate a protein controlling brain growth, a first for these mysterious molecules.READ MORE